Drug intelligence / Profile preview

A1801 ADC

Development stage: Preclinical
Lead developer: Protheragen
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

A1801 ADC is a preclinical-stage antibody-drug conjugate (ADC) developed by Protheragen. It targets Glycoprotein non-metastatic melanoma protein B (GPNMB), a transmembrane protein that is highly expressed in several types of cancer, including breast cancer and melanoma, but has limited expression in normal tissues. The drug is designed to bind to GPNMB on the surface of tumor cells, leading to internalization and the subsequent release of a cytotoxic payload to induce cell death. This targeted approach aims to maximize anti-tumor activity while minimizing off-target effects.

Targets

TUBB (Tubulin (alpha and beta subunits))GPNMB (Glycoprotein NMB)

Beyond the preview

Go deeper on A1801 ADC.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on A1801 ADC.

Explore the full profile